TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03157024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Needle (RN)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kim Sham (KS)
Study: NCT01384227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
Study: NCT01281566

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisapride
Description: 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
Study: NCT04422860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum Arabic varnish
Description: Powdered exudate from various Acacia species, especially A. senegal (Leguminosae).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proflourid Varnish,VOCO
Description: 5% NaF varnish

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI Varnish,GC Japan Inc.
Description: CPP-ACP with fluoride based varnish
Study: NCT00226759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Study: NCT02151474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Study: NCT01383993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Study: NCT04039074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Yoga
Description: A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice.
Study: NCT04162691

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue
Description: Four 4-5 mm tissues of the thymoma
Study: NCT04039074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Iyengar Yoga
Description: A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: A 12-week mindfulness intervention designed for the healthy handling of stress.
Study: NCT02151474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03302845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 MG
Description: Omeprazole 40 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Description: Famotidine 40 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg
Description: Telotristat ethyl 250 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg
Description: Telotristat ethyl 250 mg tablet
Study: NCT01515384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-133
Description: IV injection, 7.6 mCi (281.2 MBq)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-133
Description: IV injection, 7.6 mCi (281.2 MBq)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-133
Description: IV injection, 7.6 mCi (281.2 MBq)
Study: NCT04280900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)
Description: use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
Study: NCT01999803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00800332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-QbG10
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-QbG10
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT02858414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Study: NCT01040559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
Study: NCT02365714

Intervention type: RADIATION
Group type: OTHER
Intervention: CK Stereotactic Accelerated Partial Breast Irradiation
Description: Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
Study: NCT02976870

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
Study: NCT00916253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo.
Study: NCT00094055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG013736
Description: AG013736, tablets 5 mg BID daily until tumor progression or toxicity
Study: NCT04008407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection
Description: Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Description: EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs =\> 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
Study: NCT00599482

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far infrared radiation for 30 to 40 minutes during each session.
Study: NCT06476067

Intervention type: PROCEDURE
Intervention: Surgery
Description: Esophagectomy

Intervention type: PROCEDURE
Intervention: Surgery
Description: Esophagectomy

Intervention type: PROCEDURE
Intervention: Surgery
Description: Esophagectomy

Intervention type: PROCEDURE
Intervention: Surgery
Description: Esophagectomy
Study: NCT02286700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide Cream
Description: Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Moisturizing Cream
Description: Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
Study: NCT03490643

Intervention type: OTHER
Group type: OTHER
Intervention: Postural Analysis
Description: posture and plantar pressure analysis

Intervention type: OTHER
Group type: OTHER
Intervention: Postural Analysis
Description: posture and plantar pressure analysis

Intervention type: OTHER
Group type: OTHER
Intervention: plantar pressure analysis
Description: posture and plantar pressure analysis

Intervention type: OTHER
Group type: OTHER
Intervention: plantar pressure analysis
Description: posture and plantar pressure analysis
Study: NCT01783119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Barbadensis Miller

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo water
Study: NCT03452371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Traditional Care
Description: Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
Study: NCT01003496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Outpatient substance abuse treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + Long-Term Recovery Management
Description: Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
Study: NCT02791490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral tablet, 100 mg, once daily at approximately the same time each day
Study: NCT02474342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue Derived MSCs Transplantation
Description: 1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Low dose: 1x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator
Study: NCT02475148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02474342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue Derived MSCs Transplantation
Description: 1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue Derived MSCs Transplantation
Description: 1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator
Study: NCT02821702

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal ultrasound

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Study: NCT02905474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated mobile medication app
Description: Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available mobile medication app
Description: Use of mobile app to manually record and maintain medication records with no integration to databases.
Study: NCT01246440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
Study: NCT03389854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX PTT - randomized and open label
Description: Penile traction therapy in the straight and bent positions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX PTT - randomized and open label
Description: Penile traction therapy in the straight and bent positions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX PTT - randomized and open label
Description: Penile traction therapy in the straight and bent positions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RestoreX PTT - open label phase only
Description: Penile traction therapy in the straight and bent positions
Study: NCT00109707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT03561571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: butter based breakfast
Description: ingestion of proteins : 5 g, lipids 20 g, glucides 57 g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chocolate spread based breakfast
Description: ingestion of proteins 7 g, lipids 20 g, glucides 56 g
Study: NCT04509921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: asthma treatment adjustment taking account on degree of bronchial hyperresponsiveness
Description: Modification of inhaled corticosteroid dose based on the symptoms and the result of bronchial provocation (BHR group)
Study: NCT04160130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter aortic valve replacement
Description: Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
Study: NCT03030430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT1706 injection
Description: 1mg/kg, IV on day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Avastin
Description: 1mg/kg, IV on day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced Avastin
Description: 1mg/kg, IV on day 1
Study: NCT01527214

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan and education
Description: GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
Study: NCT04027933

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Based on Standard Patient Simulation
Description: In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups.
Study: NCT03728309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLITE™ XC
Description: Intradermal, needle in multiple microdepot injections across both cheeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLITE™ XC
Description: Intradermal, needle in multiple microdepot injections across both cheeks.
Study: NCT04243863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study: NCT00736346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief cognitive-behavioral treatment for Panic Disorder
Description: One two-hour session of cognitive-behavior therapy for panic disorder

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavior Therapy for Panic Disorder
Description: Seven one-hour sessions of cognitive-behavior therapy for panic disorder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 40 mg die, for 6 months